Page 3 - Frederickw Gluck News Today : Breaking News, Live Updates & Top Stories | Vimarsana

CytomX Therapeutics, Inc. (NASDAQ:CTMX – Get Rating) – Investment analysts at HC Wainwright issued their Q1 2024 earnings estimates for shares of CytomX Therapeutics in a note issued to investors on Wednesday, May 10th. HC Wainwright analyst M. Kapoor forecasts that the biotechnology company will earn ($0.18) per share for the quarter. The consensus estimate […]

CytomX Therapeutics, Inc. (NASDAQ:CTMX – Get Rating) – Stock analysts at HC Wainwright lifted their Q2 2023 earnings per share estimates for shares of CytomX Therapeutics in a research note issued on Wednesday, May 10th. HC Wainwright analyst M. Kapoor now forecasts that the biotechnology company will earn ($0.15) per share for the quarter, up […]

Formidable Asset Management LLC grew its stake in shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX – Get Rating) by 2.2% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 318,233 shares of the biotechnology company’s stock after buying an additional 6,918 shares during the period. Formidable Asset Management LLC’s holdings in CytomX Therapeutics were worth […]

Formidable Asset Management LLC grew its holdings in shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX – Get Rating) by 2.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 318,233 shares of the biotechnology company’s stock after buying an additional 6,918 shares during […]

CytomX Therapeutics, Inc. (NASDAQ:CTMX – Get Rating) saw a large increase in short interest in April. As of April 15th, there was short interest totalling 2,250,000 shares, an increase of 40.6% from the March 31st total of 1,600,000 shares. Based on an average trading volume of 1,130,000 shares, the days-to-cover ratio is presently 2.0 days. […]